Natixis’s Revance Therapeutics, Inc. RVNC Stock Holding History

Natixis’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,343	Closed	-$31.4K	–	1227
2024 Q4	$31.4K	Buy	+10,343	New	+$45.1K	﹤0.01%	914
2024 Q2	–	Sell	-79,457	Closed	-$391K	–	1180
2024 Q1	$391K	Buy	+79,457	New	+$470K	﹤0.01%	655
2023 Q3	–	Sell	-6,455	Closed	-$163K	–	1156
2023 Q2	$163K	Buy	+6,455	New	+$201K	﹤0.01%	759
2022 Q3	–	Sell	-85,000	Closed	-$1.18M	–	1198
2022 Q2	$1.18M	Buy	+85,000	New	+$1.31M	﹤0.01%	786

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Natixis's RVNC Position: Q1 2025 in Review

Natixis sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 10,343 shares — an estimated $31.4K sold.

Natixis first reported a position in RVNC in Q2 2022 and held it in 4 quarters. The position peaked at $1.18M in Q2 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Natixis reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Natixis sold 10,343 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $31.4K.
Natixis first reported a position in Revance Therapeutics, Inc. in Q2 2022 and held it in 4 quarters.
Natixis's Revance Therapeutics, Inc. position peaked at $1.18M in Q2 2022.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Natixis's 13F filing for Q1 2025, filed 14 May 2025.